Custom-Designed SNP Array Facilitates Japanese Genomic Studies
|
By LabMedica International staff writers Posted on 16 Sep 2015 |

Image: The \"Japonica Array\" contains 659,253 SNPs, including tag SNPs for imputation, SNPs of Y chromosome and mitochondria, and SNPs related to previously reported genome-wide association studies and pharmacogenomics (Photo courtesy of Tohoku Medical Megabank Organization).
Japanese genomic researchers have created a single nucleotide polymorphism (SNP) array optimized for studies on the Japanese population.
The so-called "Japonica Array" was designed by investigators at the Tohoku University Tohoku Medical Megabank Organization (Sendai, Japan). As source material, the investigators used the Tohoku Medical Megabank Organization's reference panel (referred to as the 1KJPN panel), which contains more than 20 million SNPs from whole-genome sequence data from 1070 Japanese individuals. The 1KJPN panel contains the largest number of haplotypes of Japanese ancestry to date.
Beginning with the 1KJPN panel, the investigators designed a novel custom-made SNP array, containing 659,253 SNPs, including tag SNPs for imputation, SNPs of Y- chromosome and mitochondria, and SNPs related to previously reported genome-wide association studies and pharmacogenomics.
The Japonica Array was found to provide better imputation performance for Japanese individuals than the existing commercially available SNP arrays. Imputation is an information science technique for estimating the genotype of several millions of unmeasured SNPs with a SNP array by combining it with a reference panel.
The genomic coverage of the Japonica Array was 96.9% for common SNPs; that is, almost all common SNPs were covered by this array. Furthermore, the coverage of low-frequency SNPs reached 67.2%, which was higher than those of other existing arrays.
The investigators confirmed the high quality genotyping performance of the Japonica array using the 288 samples from the 1KJPN reference panel. Results obtained from genotype screening with a high-throughput sequencer yielded an average call rate of 99.7% and an average concordance rate of 99.7%. Thus, the creation of custom-made SNP arrays based on a population-specific reference panel was shown to be a practical way to facilitate further association studies through genome-wide genotype imputations.
The study was published in the June 25, 2015, online edition of the Journal of Human Genetics.
Related Links:
Tohoku University Tohoku Medical Megabank Organization
The so-called "Japonica Array" was designed by investigators at the Tohoku University Tohoku Medical Megabank Organization (Sendai, Japan). As source material, the investigators used the Tohoku Medical Megabank Organization's reference panel (referred to as the 1KJPN panel), which contains more than 20 million SNPs from whole-genome sequence data from 1070 Japanese individuals. The 1KJPN panel contains the largest number of haplotypes of Japanese ancestry to date.
Beginning with the 1KJPN panel, the investigators designed a novel custom-made SNP array, containing 659,253 SNPs, including tag SNPs for imputation, SNPs of Y- chromosome and mitochondria, and SNPs related to previously reported genome-wide association studies and pharmacogenomics.
The Japonica Array was found to provide better imputation performance for Japanese individuals than the existing commercially available SNP arrays. Imputation is an information science technique for estimating the genotype of several millions of unmeasured SNPs with a SNP array by combining it with a reference panel.
The genomic coverage of the Japonica Array was 96.9% for common SNPs; that is, almost all common SNPs were covered by this array. Furthermore, the coverage of low-frequency SNPs reached 67.2%, which was higher than those of other existing arrays.
The investigators confirmed the high quality genotyping performance of the Japonica array using the 288 samples from the 1KJPN reference panel. Results obtained from genotype screening with a high-throughput sequencer yielded an average call rate of 99.7% and an average concordance rate of 99.7%. Thus, the creation of custom-made SNP arrays based on a population-specific reference panel was shown to be a practical way to facilitate further association studies through genome-wide genotype imputations.
The study was published in the June 25, 2015, online edition of the Journal of Human Genetics.
Related Links:
Tohoku University Tohoku Medical Megabank Organization
Latest BioResearch News
- D-Serine May Predict Immune Checkpoint Therapy Resistance in Gastric Cancer
- New Genetic Cause Identified for Neurodevelopmental Disorder
- New Genetic Discovery Could Support Precision Diabetes Care
- Inherited Genetic Differences Help Explain Variable CAR T-Cell Therapy Outcomes
- AI-Powered Genome Mapping Reveals New Layer of Alzheimer’s Disease Biology
- Genetic Variations Reveal Mechanisms Behind Sudden Cardiac Death Risk
- Immune Biomarkers Support Early Risk Stratification in Oral Precancer
- Global Genetic Map Identifies Regional Parkinson’s Variants to Support Diagnostics
- Breakthrough Genetic Map Advances Understanding of Bone Disorders
- Study Identifies Hereditary Subtype of Aggressive Prostate Cancer
- Gene Variants Linked to Pollution-Exacerbated Asthma
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
- New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
Channels
Clinical Chemistry
view channel
Rapid Breath Sensor Detects SARS-CoV-2 from Exhaled Air
Nasal swabs and polymerase chain reaction (PCR) testing have been central to identifying SARS-CoV-2, but they can be uncomfortable, slow, and logistically complex when samples require transport.... Read more
Head-to-Head Study Compares Blood Tests for Early Alzheimer’s Disease Detection
Accurate, scalable diagnostics are becoming increasingly important as disease-modifying therapies reshape Alzheimer’s disease care, yet many patients still rely on invasive cerebrospinal fluid sampling... Read more
Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy
Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read moreMolecular Diagnostics
view channel
Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers
Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer
Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read more
Machine Learning Approach Expands Epigenetic Testing for Prenatal Genetic Disorders
Prenatal genetic testing is increasingly used to identify potential neurodevelopmental conditions, but results often include variants of uncertain significance that clinicians cannot confidently classify.... Read more
New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples
Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read moreMicrobiology
view channel
Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
Artemisinin-based combination therapy remains central to controlling Plasmodium falciparum malaria, but emerging drug resistance is complicating treatment and surveillance. In Uganda and across sub-Saharan... Read more
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read morePathology
view channel
30-Minute 3D Histology Tool Supports Intraoperative Glioma Margin Assessment
Glioma surgery depends on distinguishing infiltrative tumor from functional brain tissue, but microscopic spread beyond visible margins makes this difficult. Conventional frozen sections provide rapid... Read more
AI Links Organ-Specific Aging Patterns in Histology to Blood-Based Signals
Clinical decisions often rely on chronological age, yet organs can age biologically at different rates that remain hard to assess. Noninvasive detection of organ-specific aging could support disease monitoring... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Strategic Collaboration Expands Commercial Access to Oncology Companion Diagnostics
CellCarta, a global CRO laboratory serving the biopharmaceutical industry, has announced a strategic collaboration with Tempus AI to broaden access to companion diagnostics (CDx) in oncology.... Read more







